A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo

Abstract excerpt

Targeted protein degradation offers an alternative modality to classical inhibition and holds the promise of addressing previously undruggable targets to provide novel therapeutic options for patients. Heterobifunctional molecules co-recruit a target protein and an E3 ligase, resulting in ubiquitylation and proteosome-dependent degradation of the target. In the clinic, the oral route of administration is the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Chromatin Remodeling and Cancer
• Share to Peptidase Inhibition and Analysis
• Share to Protein Degradation and Inhibitors